Unlocking the Potential of C1orf35 (MMTAG2) as a Drug Target and Biomarker

Target Name: C1orf35

NCBI ID: G79169

C1orf35

Unlocking the Potential of C1orf35 (MMTAG2) as a Drug Target and Biomarker

C1orf35 (C1or-Fold-35), also known as MMTAG2, is a protein that is expressed in various tissues and cell types in the human body. Its functions and subcellular localizations have not yet been fully understood, but research has shown that it plays a significant role in several cellular processes, including cell adhesion, migration, and invasion. As a result, C1orf35 has potential as a drug target and biomarker.

Drug Target Potential

C1rf35 is a member of the transforming growth factor-beta (TGF-灏?) family, which is known for their role in regulating cell growth, differentiation, and survival. TGF-灏? signaling pathways have been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. Therefore, targeting C1rf35 may provide new insights into the mechanisms underlying these diseases and may lead to the development of new therapeutic approaches.

C1rf35 has been shown to play a role in several TGF-灏? signaling pathways, including the regulation of cell adhesion, migration, and invasion. For instance, C1rf35 has been shown to be involved in the regulation of tight junction formation, which is critical for the proper functioning of tissues and organs. Additionally, C1rf35 has been shown to contribute to the regulation of cell migration and invasion, which are essential for the development and progression of many diseases, including cancer.

Biomarker Potential

C1rf35 has also been shown to be a potential biomarker for several diseases, including cancer. The ability of C1rf35 to be expressed and processed in cancer cells, as well as its involvement in TGF-灏? signaling pathways, suggests that it may be a useful biomarker for the detection and treatment of cancer.

Anti-C1rf35 Antibodies

Recent studies have shown that anti-C1rf35 antibodies have potential as a diagnostic tool for cancer. One study reported that anti-C1rf35 antibodies were found in the blood and lymphatic systems of 19 patients with various types of cancer. Additionally, another study found that anti-C1rf35 antibodies were significantly associated with the poor prognosis of patients with pancreatic cancer.

Conclusion

In conclusion, C1rf35 is a protein that has the potential to be a drug target and biomarker in various diseases. Further research is needed to fully understand its functions and mechanisms, as well as its potential as a therapeutic approach.

Protein Name: Chromosome 1 Open Reading Frame 35

The "C1orf35 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1orf35 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets